Movement Alert|HUTCHMED Intraday Rise 5.67% in Regular Trading, FDA Grants Orphan Drug Designation to Sovleplenib for AIHA

Market Focus11-05

On November 5, HUTCHMED rose 5.67% in Regular Trading, trading at HK$23.12, with turnover of HK$58.69 million.

The move followed the company’s announcement that the US FDA granted orphan drug designation to its oral Syk inhibitor sovleplenib for the treatment of autoimmune hemolytic anemia, adding a new regulatory milestone for the asset.

According to the company disclosure released on November 5, this is sovleplenib’s second US orphan drug designation after a prior designation granted in late October for primary immune thrombocytopenia. The update broadens the product’s rare-disease positioning and reinforces recent pipeline momentum, following other regulatory and business developments including the completion of its ex-China licensing transaction with GSK for HMPL-A830 and the US NDA submission by its partner for the ORPATHYS-TAGRISSO combination.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment